XML 39 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Jun. 30, 2023
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Annual Report true  
Document Transition Report false  
Document Period End Date Dec. 31, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus FY  
Entity Registrant Name INOZYME PHARMA, INC.  
Entity Central Index Key 0001693011  
Entity Incorporation, State or Country Code DE  
Entity File Number 001-39397  
Entity Tax Identification Number 38-4024528  
Entity Address, Address Line One 321 Summer Street  
Entity Address, Address Line Two Suite 400  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 857  
Local Phone Number 330-4340  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol INZY  
Security Exchange Name NASDAQ  
Current Fiscal Year End Date --12-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
ICFR Auditor Attestation Flag false  
Document Financial Statement Error Correction [Flag] false  
Entity Shell Company false  
Entity Public Float   $ 199,465,749
Documents Incorporated by Reference

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2023. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.

  
Auditor Firm ID 42  
Auditor Location Boston, Massachusetts  
Auditor Name Ernst & Young LLP